A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.
This is a single-arm, open-label, prospective clinical study aimed at observing and evaluating the efficacy and safety of surufatinib combined with immunotherapy and chemotherapy in the treatment of unresectable or metastatic biliary tract cancer.
Biliary Tract Cancer
DRUG: Surufatinib+Toripalimab+GEMOX
Progression free survival (PFS), Tumor assessment will be performed using radiography method every 6 weeks, until the occurrence of progressive disease (PD), using RECIST v 1.1, from randomization up to progressive disease or EOT due to any cause, assessed up to 2 year
Objective response rate (ORR), Tumor assessment will be performed using radiography method every 6 weeks until the occurrence of progressive disease (PD), using RECIST v 1.1, from randomization up to progressive disease or EOT due to any cause, assessed up to 2 year|Overall survival (OS）, Tumor assessment will be performed using radiography method every 6 weeks until the occurrence of progressive disease (PD), using RECIST v 1.1, from randomization until death due to any cause, assessed up to 3 year|Disease control rate (DCR）, Tumor assessment will be performed using radiography method every 6 weeks until the occurrence of progressive disease (PD), using RECIST v 1.1, from randomization up to progressive disease or EOT due to any cause, assessed up to 2 year|Safety and tolerance evaluated by incidence, severity and outcomes of AEs, Safety and tolerance will be evaluated by incidence, severity and outcomes of AEs and categorized by severity in accordance with the NCI CTC AE Version 5.0, from first dose to 30 days post the last dose
This is a single-arm, open-label, prospective clinical study aimed at observing and evaluating the efficacy and safety of surufatinib combined with immunotherapy and chemotherapy in the treatment of unresectable or metastatic biliary tract cancer.